Granza Bio

Granza Bio develops a novel drug delivery platform using "attack particles" from the immune system to target various diseases like cancer, autoimmune disorders, and infections. Their platform focuses on delivering therapeutic cargo to specific tissues, overcoming challenges in tropism, immunogenicity, and stability. This technology aims to transform the therapeutic landscape by offering the power of cellular therapies with the ease of antibody-based drugs.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: $7.14M

Date: 10-Jul-2024

Investors: Felicis, Refactor, Y Combinator

Markets: Biotechnology, Therapeutics, Immunology, Oncology, Drug Discovery

HQ: London, England, United Kingdom

Founded: 2023

Website: https://www.granzabio.com/

LinkedIn: https://www.linkedin.com/company/granza-bio-yc-w24/

Twitter: https://twitter.com/GranzaBio

Instagram: